Application of Biparametric Magnetic Resonance Imaging Based on PI-RADSv2.1 Combined with fPSA/tPSA in Identifying Benign and Malignant Nodules in Prostate Transitional Zone
XIANG Yang, PENG Chuanyong, FAN Ju
Lu'an People's Hospital, Anhui Lu'an 237005, China
Abstract:Objective: To investigate the application value of biparametric magnetic resonance imaging (bp-MRI) based on the Prostate Imaging-Reporting and Data System version 2.1 (PI-RADSv2.1) combined with free prostate-specific antigen (PSA)/total PSA (fPSA/tPSA) in identifying benign and malignant nodules in prostate transitional zone. Methods: A total of 107 patients with nodules in prostate transitional zone who were admitted to the hospital from March 2021 to October 2024 were reviewed. According to the results of pathological diagnosis, the patients were divided into prostate cancer (PCa) group (37 cases) and prostate hyperplasia group (70 cases). fPSA/tPSA, PI-RADSv2.1 scores, general and clinical data were compared between the two groups. Binary logistic regression analysis was used to screen influencing factors. The value of fPSA/tPSA, PI-RADSv2.1 score, and combination of the two in diagnosing benign and malignant nodules in prostate transitional zone was analyzed using the receiver operating characteristic (ROC) curves. Results: There was a statistically significant difference in the grading of PI-RADSv2.1 scores between the two groups (P<0.05). fPSA and tPSA levels of the PCa group were higher than those of the BPH group (P<0.05). However, the proportions of patients with age, hypertension and diabetes in the two groups were similar (P>0.05). Binary logistic regression analysis showed that fPSA/tPSA and PI-RADSv2.1 score were influencing factors of nodules in prostate transitional zone (P<0.05). When fPSA/tPSA and PI-RADSv2.1 score were used to diagnose nodules in prostate transitional zone separately, the area under the curve (AUC) of PI-RADSv2.1 score was the greatest, which was 0.889. With 3 points as the optimal cutoff value, its diagnostic sensitivity and specificity were 86.49% and 88.57%. Based on binary logistic regression analysis, a joint diagnosis model was constructed as follows: logit(p)=-4.327+1.825 * PI-RADSv2.1 score -15.730 * fPSA/tPSA. Hosmer-Lemeshow test showed χ2=7.585, P=0.475. ROC curve showed that the AUC of joint diagnosis was 0.936. With 0.48 as the optimal cutoff value, the sensitivity and specificity of joint diagnosis were 83.78% and 94.29%. Conclusion: Both fPSA/tPSA and PI-RADSv2.1 score can be used for clinical diagnosis of benign and malignant nodules in prostate transitional zone, and diagnostic value of combination of the two is higher.
项杨, 彭传勇, 范菊. 基于PI-RADSv2.1的双参数磁共振成像联合fPSA/tPSA在鉴别前列腺移行带良恶性结节中的应用[J]. 河北医学, 2025, 31(7): 1195-1200.
XIANG Yang, PENG Chuanyong, FAN Ju. Application of Biparametric Magnetic Resonance Imaging Based on PI-RADSv2.1 Combined with fPSA/tPSA in Identifying Benign and Malignant Nodules in Prostate Transitional Zone. HeBei Med, 2025, 31(7): 1195-1200.
[1] Malshy K,Ochsner A,Ortiz R,et al.Comparison of the incidence of clinically significant prostate cancer in patients with isolated peripheral versus transitional zone PIRADS 3 lesions[J].Urologia,2025,92(1):51-58. [2] 林俊坤,钟治平,陈志远,等.PI-RADS v2.1联合ADC值对前列腺移行带癌的诊断效能评估[J].中国医学计算机成像杂志,2022,28(5):510-516. [3] National Cancer Center.Prostate cancer expert committee of national cancer quality control center.Quality control index for standardized diagnosis and treatment of prostate cancer in China (2022 edition)[J].Zhonghua Zhong Liu Za Zhi,2022,44(10):1011-1016. [4] 董喆,张云,王海屹,等.双参数与多参数MRI对前列腺特异性抗原灰区临床显著性前列腺癌诊断效能比较[J].国际医学放射学杂志,2024,47(3):328-334. [5] 韩卫,赵亚琦,张兰胜,等.游离和总前列腺特异性抗原比值、外周血中性粒细胞和淋巴细胞比值、白细胞介素6、前列腺健康指数密度检测在前列腺癌早期诊断中的应用[J].肿瘤研究与临床,2023,35(6):439-444. [6] 李拔森,刘良进,阮亚俊,等.基于PI-RADS v2.1磁共振扩散加权成像对前列腺癌内分泌治疗疗效的预测价值[J].肿瘤防治研究,2023,50(7):694-699. [7] 赵旭,霍日查,邢征宇,等.前列腺影像报告和数据系统对经会阴认知融合靶向穿刺诊断前列腺癌的预测价值[J].中国医学影像学杂志,2023,31(8):872-876,881. [8] 余丽娜,罗翠,刘双苔,等.前列腺癌根治术后尿失禁保守治疗的最佳证据总结[J].中国临床研究,2023,36(5):782-788. [9] Bouaod W,Zakoko A M,Asif H,et al.The potentiality of prostate-specific antigen as a prognostic biomarker in breast cancer[J].Cureus,2023,15(9):44621. [10] Garmer M,Gronemeyer D,van de Loo T,et al.Morphologic perfusion patterns and PI-RADSv2.1 in transition zone prostate cancer[J].Abdom Radiol (NY),2023,48(11):3488-3497. [11] 沈红梅,刘培龙,顾屏,等.精子相关抗原9联合PSAD、fPSA/tPSA比值诊断PSA灰区前列腺癌的临床研究[J].癌变.畸变.突变,2024,36(2):129-132,163.